Venture Prepares for Structured Acquisitions

With Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say venture investors, that means structured acquisitions of biotech firms are likely to increase as pharmaceutical acquirers gain more leverage over cash-strapped firms in deal negotiations.